Bristol Myers Squibb stock steadies after earnings beat and guidance hike

Published on 09/10/2026 at 14:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bristol Myers Squibb stock closed at USD 64.69 on September 9, 2026 on the NYSE, near the upper third of its 52-week range after a recent pullback. The company’s Q2 2026 revenue grew 6% year over year to USD 13.0 billion and non-GAAP EPS rose to USD 2.04, alongside higher full-year guidance.

Wissenschaftlerin im Schutzanzug blickt durch ein Fluoreszenzmikroskop auf leuchtende Zellkulturen in einem sterilen Onkologielabor — Bristol-Myers Squibb US0897961004 zeigt Onkologieforscherin am Mikroskop mit leuchtenden Zellkulturen im sterilen Labor, Illustration mit AI erstellt.

Bristol Myers Squibb stock (ISIN US0897961004) closed at USD 64.69 on the NYSE on September 9, 2026, marking a 3.19 percent decline versus the previous day and leaving the shares near the upper third of their 52-week range between USD 42.52 and USD 68.64 per MarketWatch data, according to Ad-hoc-news on September 10, 2026.

Q2 2026 results and raised guidance

As StockTitan reported in an 8-K summary for Bristol Myers Squibb, the company delivered second-quarter 2026 total revenue of USD 12,973 million, up 6 percent year over year, while net income attributable to the company reached USD 3,317 million for the period.

According to the same StockTitan filing overview, Bristol Myers Squibb’s Growth Portfolio generated USD 7,560 million in Q2 2026 revenue, up 15 percent year over year, while the Legacy Portfolio contributed USD 5,422 million, down 4 percent as generic competition weighed on older brands.

GAAP diluted EPS for Q2 2026 increased to USD 1.62 from USD 0.64 a year earlier, and non-GAAP diluted EPS rose to USD 2.04 from USD 1.46, meaning adjusted earnings per share were 39.7 percent higher than in the prior-year quarter, according to StockTitan.

Product mix and outlook

As Yahoo Finance highlighted on September 9, 2026, Eliquis revenue grew 22 percent year over year in Q2 2026 to USD 4,481 million, underscoring the continued strength of the company’s leading cardiovascular franchise.

According to Yahoo Finance, Bristol Myers Squibb raised its full-year 2026 total revenue guidance from approximately USD 46.0–47.5 billion to USD 49.0–50.0 billion and increased its non-GAAP EPS outlook to a range of USD 6.75–7.00, reflecting stronger-than-expected portfolio momentum, particularly in the Growth Portfolio.

The same StockTitan summary notes that Bristol Myers Squibb now assumes worldwide Eliquis revenue growth of 20–25 percent for 2026 and operating expenses of about USD 16,500 million, which together frame the earnings guidance investors are watching.

Analyst expectations and valuation context

Consensus expectations compiled by Yahoo Finance on September 10, 2026 show that analysts on average forecast 2026 revenue of USD 49.85 billion for Bristol Myers Squibb, with estimates ranging roughly between USD 49.32 billion and USD 50.35 billion.

The same Yahoo Finance analysis page indicates that the average analyst estimate for 2026 non-GAAP EPS stands at USD 6.95, with forecasts between about USD 6.80 and USD 7.15, broadly consistent with the company’s own guidance range.

Looking at valuation and earnings momentum, Zacks noted on September 9, 2026 that Bristol Myers Squibb trades at about 9.85 times forward earnings, above its long-term mean of 8.53 times but still well below the large-cap pharma industry’s average multiple of 18.70 times, while shares have gained 19.9 percent year to date compared with 10.1 percent for the broader industry.

Stock level and trading data

Per a price snapshot shown by Seeking Alpha, Bristol Myers Squibb shares last changed hands at USD 64.41 on the NYSE at 4:00 p.m. Eastern Time on September 9, 2026, with a modest intraday decline of 0.43 percent versus the prior close and pre-market indications slightly above that level.